Last reviewed · How we verify

NCT03092583: METYLAS

Analysis of DNA Methylation in Spondyloarthritis

Completed NA Last updated 1 February 2021
What this trial tests

NA trial testing Blood sample in Spondylitis, Ankylosing in 184 participants. Completed in 7 October 2020.

Timeline
15 February 2017
Primary endpoint
7 October 2020
7 October 2020

Quick facts

Lead sponsorCentre Hospitalier Universitaire de Besancon
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposebasic science
Enrollment184
Start date15 February 2017
Primary completion7 October 2020
Estimated completion7 October 2020
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire de Besancon

Who can join

Adults 18 to 80, any sex, with Spondylitis, Ankylosing or Axial Spondyloarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this project is to quantify global DNA methylation in patients with Ankylosing Spondylitis or Axial Spondyloarthritis as compared with control subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Blood sample

Trials testing the same drug.

Other recruiting trials for Spondylitis, Ankylosing

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire de Besancon trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03092583.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing